PRESS RELEASE published on 01/22/2024 at 08:30, 2 years 7 months ago Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024. Abivax Obefazimod Ulcerative Colitis Crohn’s Disease Clinical Trials
PRESS RELEASE published on 10/24/2023 at 22:05, 2 years 10 months ago Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE published on 10/20/2023 at 16:00, 2 years 10 months ago Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
PRESS RELEASE published on 10/20/2023 at 15:45, 2 years 10 months ago Abivax announces trading resumption of its ordinary shares on Euronext Paris
PRESS RELEASE published on 10/20/2023 at 15:00, 2 years 10 months ago Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE published on 10/20/2023 at 08:45, 2 years 10 months ago Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PRESS RELEASE published on 10/19/2023 at 00:00, 2 years 10 months ago Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
PRESS RELEASE published on 10/16/2023 at 17:40, 2 years 11 months ago Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
PRESS RELEASE published on 10/02/2023 at 18:00, 2 years 11 months ago Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
PRESS RELEASE published on 09/29/2023 at 23:00, 2 years 11 months ago Abivax files registration statement for proposed initial public offering in the United States
Published on 09/16/2026 at 23:45, 5 hours 46 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 16:55, 12 hours 36 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 14 hours 31 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 15 hours 31 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/17/2026 at 04:25, 1 hour 6 minutes ago Zhou Jianjun from Huawei: Building a Grid-Interactive AIDC Solution to Maximize Tokens Per Watt
Published on 09/16/2026 at 23:45, 5 hours 46 minutes ago WESCAN GOLDFIELDS COMMENCES UAV MAGNETIC AND LIDAR SURVEYS AT MUNRO LAKE PROJECT
Published on 09/16/2026 at 22:33, 6 hours 57 minutes ago EQS-Adhoc: Bilfinger adjusts outlook for 2026 and resolves program “Agile”
Published on 09/16/2026 at 21:15, 8 hours 16 minutes ago Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 9 hours 3 minutes ago EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 17:45, 11 hours 46 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 22 hours 31 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 11 hours ago Report on the Combined General Meeting of the 10th of September 2026
